Vaccines and melanoma

Clinical and Experimental Dermatology

Volumn 27, Issue 7, 2002, Pages 597-601

  Nestle, F O ^a  

^a Department of Dermatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; MELANOMA ANTIGEN; VACCINE;

CELL ASSAY; DENDRITIC CELL; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 0036454684     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01152.x     Document Type: Review

References (27)

1. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
2. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today 1999; 20: 5-7.
3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000; 6 (suppl. 1): S11-4.
4. Chapman PB, Parkinson DR, Kirkwood JM. Biologic therapy. In: Balch CMAN, Houghton A, Sober J, Soong SJ, eds. Cutaneous Melanoma. St Louis: Quality Medical Publishing, 1998: 419-36.
5. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996; 88: 1635-44.
6. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
7. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 1997; 27: 81-6.
8. Hofbauer GF, Schaefer C, Noppen C et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution. Am J Pathol 1997; 151: 1549-53.
9. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
10. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001; 7: 1882-7.
11. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25: 623-35.
12. Berd D. Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 2001; 19: 2565-70.
13. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin Oncol 1998; 25: 611-22.
14. Wallack MK, Sivanandham M, Balch CM et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77 [discussion 77-9].
15. Livingston P. The unfulfilled promise of melanoma vaccines. Clin Cancer Res 2001; 7: 1837-8.
16. Hershey P. Current status of vaccines in the treatment of melanoma (Abstract). Melanoma Res 2001; 11 (suppl. 1): 14.
17. Sun Y, Paschen A, Schadendorf D. Cell-based vaccination against melanoma - Background, preliminary results, and perspective. J Mol Med 1999; 77: 593-608.
18. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
19. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
20. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-30.
21. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: Recent developments. Oncology 2001; 60: 1-7.
22. Agarwala SS, Kirkwood JM. Adjuvant therapy of melanoma. Semin Surg Oncol 1998; 14: 302-10.
23. Steinman RM. Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68: 106-66.
24. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001; 7: 761-5.
25. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
26. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
27. Romero PMJ, Pittet D, Valmori DE et al. Immune monitoring in cancer immunotherapy. Ernst Schering Res Found Workshop 2000; 30: 75-97.